Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02128087 · ClinicalTrials.gov registry record · NA

Improving Drug Adherence Among Adolescents in Uganda Using SMS Reminders

A NA study of Human Immunodeficiency Virus, sponsored by RAND.

Completed
Registry status
NA
Development phase
330
Enrollment target
3
Study locations

NCT02128087: Completed NA study of Human Immunodeficiency Virus, sponsored by RAND.

NCT02128087 is a NA study of Human Immunodeficiency Virus that has completed, run by RAND. The registered enrollment target is 330 participants, above the 175-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (89% higher). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02128087, a NA study of Human Immunodeficiency Virus, has completed, sponsored by RAND.

COMPLETED
Registry status
NA
Development phase
330 participants
Enrollment target
3
Study locations

Study Summary

In this project the investigators develop and test a short message service (SMS) intervention based on the Information Motivation and Behavior skills (IMB) model. Reminding Adolescents To Adhere (RATA) prompts youths at two clinics in Uganda to take their medications and offers social support via weekly text messages. The investigators propose to adapt their previous successful SMS-intervention to the specific needs of youths and to evaluate the relative effectiveness of one-way versus two-way text messages (where two-way messages allow youths to respond to messages and we hypothesize that this may increase perceived social support that may be important for youth populations). We will also test the effectiveness of SMS messages over the longer-term (2 years), for which currently no information is available.

Primary Outcome

Medication Event Monitoring System (MEMS)-cap data will be collected continuously over the course of the 24-month study period allowing us to investigate daily adherence and its timing. MEMS caps data indicating the date and time when the participant opened their pill bottle (either one of the ART medications or prophylaxis if not on ART yet) will be used to calculate the primary outcome variable of adherence (# of actual bottle openings / # of prescribed bottle openings).

Interventions

  • BEHAVIORAL Two-way SMS intervention
  • BEHAVIORAL One-way SMS intervention group

Study Locations (3)

Other

  • Infectious Diseases Institute - Kampala
  • Mildmay Uganda - Kampala

California

  • RAND - Santa Monica

Trial Details

FieldValue
Enrollment Target 330 participants
Start Date 2013-02
Est. Completion 2017-03-31
Phase NA
RAND

78 total trials

What the finished NCT02128087 record still lists

NCT02128087 is an interventional study that assigns participants to a tested intervention. The registered 330 participants enrollment target is mid-sized for trials with a published cap, above the 175-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (89% higher).

The record links to 1 condition, with Human Immunodeficiency Virus appearing as the primary indexed condition, and to 2 interventions - of which Two-way SMS intervention is the first listed.

NCT02128087 reports a single indexed study location in Other, California.

Frequently Asked Questions

What is clinical trial NCT02128087 about?

NCT02128087 is a clinical study titled "Improving Drug Adherence Among Adolescents in Uganda Using SMS Reminders". In this project the investigators develop and test a short message service (SMS) intervention based on the Information Motivation and Behavior skills (IMB) model. Reminding Adolescents To Adhere (RATA) prompts youths at two clinics in Uganda to take their medications and offers social support via we...

What is the current status of trial NCT02128087?

This trial is currently completed. It is a NA study. The enrollment target is 330 participants. The study started on 2013-02. Estimated completion is 2017-03-31.

What conditions does trial NCT02128087 study?

This clinical trial studies the following conditions: Human Immunodeficiency Virus.

What interventions are being tested in trial NCT02128087?

The interventions under investigation include: Two-way SMS intervention (BEHAVIORAL), One-way SMS intervention group (BEHAVIORAL).

Who is sponsoring clinical trial NCT02128087?

This trial is sponsored by RAND, which has 78 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02128087 being conducted?

This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Human Immunodeficiency Virus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02128087's enrollment target sits among peer trials

330 8th of 39 higher than 32 of 39 other Human Immunodeficiency Virus trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Human Immunodeficiency Virus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00359684 · 330 participants

    Use of Cysteamine in the Treatment of Cystinosis

  • NCT03817502 · 330 participants · Phase 3

    Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia

  • NCT03922724 · 330 participants · Phase 2

    Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

  • NCT03932773 · 330 participants · NA

    Multi-site Confirmatory Efficacy Treatment Trial of Combat-related PTSD

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02128087, the US trial registry maintained by the National Library of Medicine. NCT02128087 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.